CriticalAntiepileptics. Barbiturates×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
The liver breaks down ranolazine mainly through the enzyme CYP3A4 and to a lesser extent through CYP2D6, and ranolazine is also a substrate of the transporter P-glycoprotein (ranolazine label, US Food and Drug Administration, FDA). Phenobarbital strongly induces cytochrome P450 enzymes and P-glycoprotein, so many drugs are cleared faster and work less well (phenobarbital summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP3A4 inducers make ranolazine ineffective: rifampicin 600 mg daily lowers ranolazine levels by about 95%. Phenobarbital appears in the ranolazine documents in the same group of inducers (ranolazine SmPC, European Medicines Agency, EMA, and ranolazine label, FDA). There are no figures for phenobarbital itself in the documents.
Symptoms
Ranolazine is given to adults with stable angina when first-line antianginal drugs do not control symptoms or are not tolerated (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). With phenobarbital, ranolazine loses its effect (ranolazine SmPC, EMA), and angina attacks (pressing pain behind the breastbone on exertion) may come back or become more frequent. The fall in ranolazine levels itself causes no symptoms. Stopping phenobarbital abruptly after long use in a person dependent on it can cause delirium, seizures and even death (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is contraindicated: ranolazine must not be taken with CYP3A inducers, and phenobarbital is named among them (ranolazine label, US Food and Drug Administration, FDA). Under the European ranolazine summary of product characteristics (SmPC), ranolazine should not be used in patients taking CYP3A4 inducers, phenobarbital among them, and should not be started while they are taken (ranolazine SmPC, European Medicines Agency, EMA). Ranolazine does not appear in the phenobarbital SmPC. As a strong enzyme inducer, however, phenobarbital interacts in a clinically relevant way with many drug groups (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Do not stop phenobarbital abruptly: reduce the dose gradually (phenobarbital SmPC, AEMPS). There is no documented interval between stopping phenobarbital and starting ranolazine.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- AEMPS: Ficha técnica: Fenobarbital (nº registro 35052), sección 4.5 (2025)– AEMPS, CIMA, nº registro 35052 (Luminal 100 mg comprimidos), revisión 07/2025 (texto de marzo de 2025), secciones 4.2, 4.4 y 4.5
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5